Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells

Oncology Reports

Volumn 27, Issue 3, 2012, Pages 849-853

  Knutson, Andrew Kekapa'a ^a   Welsh, Jennifer ^a   Taylor, Travis ^b   Roy, Somdutta ^c   Wang, Wei Lin Winnie ^a,d   Tenniswood, Martin ^a,d  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b INDIANA UNIVERSITY SOUTH BEND   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Breast cancer; Cell death; Gene expression; Histone deacetylase inhibitors; Mitotic catastrophe; Protein acetylation

Indexed keywords

7 PHENYL 2,4,6 HEPTATRIENOIC HYDROXAMIC ACID; AURORA A KINASE; CG 1521; CYCLIN B1; CYCLIN D1; GROWTH DIFFERENTIATION FACTOR 15; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; POLO LIKE KINASE 1; PROTEIN; PROTEIN BNIP3; PROTEIN CDC25A; PROTEIN KNTC2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; VORINOSTAT;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL COUNT; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE INDUCTION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STEADY STATE; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CENTROSOME; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MITOTIC SPINDLE APPARATUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863069438     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1590     Document Type: Article

References (23)

1. Lane AA and Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468, 2009.
2. Selvi RB and Kundu TK: Reversible acetylation of chromatin: implication in regulation of gene expression, disease and therapeutics. Biotechnol J 4: 375-390, 2009.
3. Haberland M, Montgomery RL and Olson EN: The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32-42, 2009.
4. Gregoretti IV, Lee YM and Goodson HV: Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17-31, 2004. (Pubitemid 38429783)
5. Yang XJ and Seto E: The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 9: 206-218, 2008.
6. Haigis MC and Sinclair DA: Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5: 253-295, 2010.
7. Müller S and Krämer OH: Inhibitors of HDACs - effective drugs against cancer? Curr Cancer Drug Targets 10: 210-228, 2010.
8. + dependent histone deacetylases (sirtuins). Curr Pharm Des 14: 562-573, 2008.
9. Peck B, Chen CY, Ho KK et al: SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther 9: 844-855, 2010.
10. Roy S, Jeffrey R and Tenniswood M: Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells. Mol Cancer Ther 7: 1931-1939, 2008.
11. Roy S, Packman K, Jeffrey R and Tenniswood M: Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 12: 482-491, 2005. (Pubitemid 40662846)
12. Roy S and Tenniswood M: Site-specific acetylation of p53 directs selective transcription complex assembly. J Biol Chem 282: 4765-4771, 2007. (Pubitemid 47100922)
13. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
14. Venugopal B and Evans TR: Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 18: 1658--1671, 2011.
15. Marson CM: Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer. Anticancer Agents Med Chem 9: 661-692, 2009.
16. Galluzzi L, Vitale I, Abrams JM et al: Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ: July 15, 2011 (Epub ahead of print). doi: 10.1038/cdd.2011.96, 2011.
17. Wang D: Computational studies on histone deacetylases and the design of selective histone deacetylase inhibitors. Curr Top Med Chem 9: 241-256 2009.
18. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W: Acetylation is indispensable for p53 activation. Cell 133: 612-626, 2008. (Pubitemid 351636297)
19. Kim GW and Yang XJ: Comprehensive lysine acetylomes emerging from bacteria to humans. Trends Biochem Sci 36: 211-220, 2011.
20. Spange S, Wagner T, Heinzel T, and Krämer OH: Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 41: 185-198, 2009.
21. Buchwald M, Krämer OH and Heinzel T: HDACi-targets beyond chromatin. Cancer Lett 280: 160-167, 2009.
22. Harms KL and Chen X: Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 67: 3145-3152, 2007. (Pubitemid 46724851)
23. Zhang XH, Rao M, Loprieato JA, Hong JA et al: Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther 7: 1388-1397, 2008.